The human papillomavirus family and its role in carcinogenesis

Seminars in Cancer Biology

Volumn 26, Issue , 2014, Pages 13-21

  Tommasino, Massimo ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cancer; Cellular transformation; E6 and E7 oncoproteins; Human papillomavirus; Viral persistence

Indexed keywords

DNA; ONCOPROTEIN; VIRUS PROTEIN; PROTEIN E6; PROTEIN E7;

APOPTOSIS; CARCINOGENIC ACTIVITY; CELL CYCLE; CELL DIFFERENTIATION; CELL TRANSFORMATION; DISEASE ASSOCIATION; DNA SEQUENCE; E6 GENE; E7 GENE; GENE EXPRESSION; GENE INTERACTION; GENITAL TRACT CANCER; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; MOLECULAR MECHANICS; NONHUMAN; ONCOGENE; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; REGULATORY MECHANISM; REVIEW; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS; ALPHAPAPILLOMAVIRUS; COMPLICATION; GENETICS; METABOLISM; NEOPLASMS; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS GENOME; GENE PRODUCT; LIFE CYCLE; OPEN READING FRAME; PHYLOGENETIC TREE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION; VIRAL TROPISM; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

ALPHAPAPILLOMAVIRUS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; GENOME, VIRAL; HUMANS; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; VIRAL PROTEINS;

EID: 84901845939     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.11.002     Document Type: Review

References (123)

1. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401(1):70-79.
2. de Villiers E.M. Cross-roads in the classification of papillomaviruses. Virology 2013, 445(1-2):2-10.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
4. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10(4):321-322.
5. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
6. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
7. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128(4):927-935.
8. Marur S., D'Souza G., Westra W.H., Forastiere A.A. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010, 11(8):781-789.
9. Halec G., Holzinger D., Schmitt M., Flechtenmacher C., Dyckhoff G., Lloveras B., et al. Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. Br J Cancer 2013, 109(1):172-183.
10. Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
11. Hasan U.A., Bates E., Takeshita F., Biliato A., Accardi R., Bouvard V., et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007, 178(5):3186-3197.
12. Schiffman M., Herrero R., Desalle R., Hildesheim A., Wacholder S., Rodriguez A.C., et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337(1):76-84.
13. Yuan H., Zhou D., Wang J., Schlegel R. Divergent human papillomavirus associated with recurrent respiratory papillomatosis with lung involvement. Genome Announc 2013, 1(4).
14. Pfister H. Chapter 8: human papillomavirus and skin cancer. J Natl Cancer Inst Monogr 2003, 31:52-56.
15. Lambert P.F., Balsitis S.J., Shai A., Simonson S.J.S., Williams S.M.G. Transgenic mouse models for the in vivo analysis of papillomavirus oncogene function. Papillomavirus research: from natural history to vaccine and beyond 2006, 213-228. Caister Academic Press, Norfolk, UK. M. Saveria Campo (Ed.).
16. Astori G., Lavergne D., Benton C., Hockmayr B., Egawa K., Garbe C., et al. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol 1998, 110(5):752-755.
17. de Koning M.N., Weissenborn S.J., Abeni D., Bouwes Bavinck J.N., Euvrard S., Green A.C., et al. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. J Gen Virol 2009, 90(Pt 7):1611-1621.
18. Farzan S.F., Waterboer T., Gui J., Nelson H.H., Li Z., Michael K.M., et al. Cutaneous alpha, beta and gamma human papillomaviruses in relation to squamous cell carcinoma of the skin: a population-based study. Int J Cancer 2013, 133(7):1713-1720.
19. Iannacone M.R., Gheit T., Waterboer T., Giuliano A.R., Messina J.L., Fenske N.A., et al. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2012, 21(8):1303-1313.
20. Karagas M.R., Waterboer T., Li Z., Nelson H.H., Michael K.M., Bavinck J.N., et al. Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. Br Med J 2010, 341:c2986.
21. Bouwes Bavinck J.N., Neale R.E., Abeni D., Euvrard S., Green A.C., Harwood C.A., et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010, 70(23):9777-9786.
22. Forslund O., Iftner T., Andersson K., Lindelof B., Hradil E., Nordin P., et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007, 196(6):876-883.
23. Waterboer T., Abeni D., Sampogna F., Rother A., Masini C., Sehr P., et al. Serological association of beta and gamma human papillomaviruses with squamous cell carcinoma of the skin. Br J Dermatol 2008, 159(2):457-459.
24. Iannacone M.R., Gheit T., Pfister H., Giuliano A.R., Messina J.L., Fenske N.A., et al. Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int J Cancer 2013, [Epub ahead of print]. 10.1002/ijc.28552.
25. Vasiljevic N., Hazard K., Dillner J., Forslund O. Four novel human betapapillomaviruses of species 2 preferentially found in actinic keratosis. J Gen Virol 2008, 89(Pt 10):2467-2474.
26. Weissenborn S.J., Nindl I., Purdie K., Harwood C., Proby C., Breuer J., et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005, 125(1):93-97.
27. Snijders P.J., Hogewoning C.J., Hesselink A.T., Berkhof J., Voorhorst F.J., Bleeker M.C., et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer 2006, 119(5):1102-1107.
28. Ananthaswamy H.N., Loughlin S.M., Cox P., Evans R.L., Ullrich S.E., Kripke M.L. Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nat Med 1997, 3(5):510-514.
29. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001, 63(1-3):8-18.
30. Preston D.S., Stern R.S. Nonmelanoma cancers of the skin. N Engl J Med 1992, 327(23):1649-1662.
31. Iftner T., Elbel M., Schopp B., Hiller T., Loizou J.I., Caldecott K.W., et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002, 21(17):4741-4748.
32. Giampieri S., Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004, 90(11):2203-2209.
33. Wallace N.A., Robinson K., Howie H.L., Galloway D.A. HPV 5 and 8 E6 abrogate ATR activity resulting in increased persistence of UVB induced DNA damage. PLoS Pathog 2012, 8(7):e1002807.
34. Viarisio D., Mueller-Decker K., Kloz U., Aengeneyndt B., Kopp-Schneider A., Grone H.J., et al. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011, 7(7):e1251002.
35. Boyle J., MacKie R.M., Briggs J.D., Junor B.J., Aitchison T.C. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet 1984, 1(8379):702-705.
36. Kiviat N.B. Papillomaviruses in non-melanoma skin cancer: epidemiological aspects. Semin Cancer Biol 1999, 9(6):397-403.
37. Walder B.K., Jeremy D., Charlesworth J.A., Macdonald G.J., Pussell B.A., Robertson M.R. The skin and immunosuppression. Australas J Dermatol 1976, 17(3):94-97.
38. Walder B.K., Robertson M.R., Jeremy D. Skin cancer and immunosuppression. Lancet 1971, 2(7737):1282-1283.
39. Proby C.M., Harwood C.A., Neale R.E., Green A.C., Euvrard S., Naldi L., et al. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. Am J Transplant 2011, 11(7):1498-1508.
40. Accardi R., Dong W., Smet A., Cui R., Hautefeuille A., Gabet A.S., et al. Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep 2006, 7(3):334-340.
41. Caldeira S., Zehbe I., Accardi R., Malanchi I., Dong W., Giarre M., et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003, 77(3):2195-2206.
42. Gabet A.S., Accardi R., Bellopede A., Popp S., Boukamp P., Sylla B.S., et al. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 2008, 22(2):622-632.
43. Howie H.L., Koop J.I., Weese J., Robinson K., Wipf G., Kim L., et al. Beta-HPV 5 and 8 E6 promote p300 degradation by blocking AKT/p300 association. PLoS Pathog 2011, 7(8):e1002211.
44. Muench P., Probst S., Schuetz J., Leiprecht N., Busch M., Wesselborg S., et al. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 2010, 70(17):6913-6924.
45. Muschik D., Braspenning-Wesch I., Stockfleth E., Rosl F., Hofmann T.G., Nindl I. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS ONE 2011, 6(11):e27655.
46. Viarisio D., Decker K.M., Aengeneyndt B., Flechtenmacher C., Gissmann L., Tommasino M. Human papillomavirus type 38 E6 and E7 act as tumour promoters during chemically induced skin carcinogenesis. J Gen Virol 2013, 94(Pt 4):749-752.
47. Dong W., Kloz U., Accardi R., Caldeira S., Tong W.M., Wang Z.Q., et al. Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol 2005, 79(23):14899-14908.
48. Michel A., Kopp-Schneider A., Zentgraf H., Gruber A.D., de Villiers E.M. E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol 2006, 80(22):11153-11164.
49. Schaper I.D., Marcuzzi G.P., Weissenborn S.J., Kasper H.U., Dries V., Smyth N., et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005, 65(4):1394-1400.
50. Fertey J., Hurst J., Straub E., Schenker A., Iftner T., Stubenrauch F. Growth inhibition of HeLa cells is a conserved feature of high-risk human papillomavirus E8^E2C proteins and can also be achieved by an artificial repressor protein. J Virol 2011, 85(6):2918-2926.
51. Chen Z., Schiffman M., Herrero R., Desalle R., Burk R.D. Human papillomavirus (HPV) types 101 and 103 isolated from cervicovaginal cells lack an E6 open reading frame (ORF) and are related to gamma-papillomaviruses. Virology 2007, 360(2):447-453.
52. Nobre R.J., Herraez-Hernandez E., Fei J.W., Langbein L., Kaden S., Grone H.J., et al. E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol 2009, 83(7):2907-2916.
53. Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012, 30(Suppl. 5):F55-F70.
54. Shafti-Keramat S., Handisurya A., Kriehuber E., Meneguzzi G., Slupetzky K., Kirnbauer R. Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J Virol 2003, 77(24):13125-13135.
55. Joyce J.G., Tung J.S., Przysiecki C.T., Cook J.C., Lehman E.D., Sands J.A., et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999, 274(9):5810-5822.
56. Evander M., Frazer I.H., Payne E., Qi Y.M., Hengst K., McMillan N.A. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol 1997, 71(3):2449-2456.
57. Sibbet G., Romero-Graillet C., Meneguzzi G., Campo M.S. alpha6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4. J Gen Virol 2000, 81(Pt 2):327-334.
58. Day P.M., Lowy D.R., Schiller J.T. Papillomaviruses infect cells via a clathrin-dependent pathway. Virology 2003, 307(1):1-11.
59. Bousarghin L., Touze A., Sizaret P.Y., Coursaget P. Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol 2003, 77(6):3846-3850.
60. Gambhira R., Karanam B., Jagu S., Roberts J.N., Buck C.B., Bossis I., et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007, 81(24):13927-13931.
61. Kawana Y., Kawana K., Yoshikawa H., Taketani Y., Yoshiike K., Kanda T. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol 2001, 75(5):2331-2336.
62. Woodham A.W., Da Silva D.M., Skeate J.G., Raff A.B., Ambroso M.R., Brand H.E., et al. The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection. PLoS ONE 2012, 7(8):e43519.
63. Surviladze Z., Dziduszko A., Ozbun M.A. Essential roles for soluble virion-associated heparan sulfonated proteoglycans and growth factors in human papillomavirus infections. PLoS Pathog 2012, 8(2):e1002519.
64. Ostör A.G. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993, 12(2):186-192.
65. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P., Tan T., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9(6):347-356.
66. Rodriguez A.C., Schiffman M., Herrero R., Wacholder S., Hildesheim A., Castle P.E., et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008, 100(7):513-517.
67. Shiels M.S., Pfeiffer R.M., Gail M.H., Hall H.I., Li J., Chaturvedi A.K., et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103(9):753-762.
68. Clifford G.M., Franceschi S. Cancer risk in HIV-infected persons: influence of CD4(+) count. Future Oncol 2009, 5(5):669-678.
69. Schiffman M.H., Haley N.J., Felton J.S., Andrews A.W., Kaslow R.A., Lancaster W.D., et al. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res 1987, 47(14):3886-3888.
70. Moreno V., Munoz N., Bosch F.X., de Sanjose S., Gonzalez L.C., Tafur L., et al. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995, 4(5):459-467.
71. Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M., et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002, 359(9312):1085-1092.
72. Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002, 359(9312):1093-1101.
73. Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010, 10(8):550-560.
74. Howie H.L., Katzenellenbogen R.A., Galloway D.A. Papillomavirus E6 proteins. Virology 2009, 384(2):324-334.
75. McLaughlin-Drubin M.E., Meyers J., Munger K. Cancer associated human papillomaviruses. Curr Opin Virol 2012, 2(4):459-466.
76. Banks L., Pim D., Thomas M. Human tumour viruses and the deregulation of cell polarity in cancer. Nat Rev Cancer 2012, 12(12):877-886.
77. Grabowska A.K., Riemer A.B. The invisible enemy - how human papillomaviruses avoid recognition and clearance by the host immune system. Open Virol J 2012, 6:249-256.
78. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985, 314(6006):111-114.
79. Wentzensen N., Vinokurova S., von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004, 64(11):3878-3884.
80. Butz K., Ristriani T., Hengstermann A., Denk C., Scheffner M., Hoppe-Seyler F. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003, 22(38):5938-5945.
81. Ghittoni R., Accardi R., Hasan U., Gheit T., Sylla B., Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40:1-13.
82. Zanier K., ould M'hamed ould S.A., Boulade-Ladame C., Rybin V., Chappelle A., Atkinson A., et al. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 2012, 20(4):604-617.
83. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., et al. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 2006, 21(5):665-678.
84. Zanier K., Charbonnier S., Sidi A.O., McEwen A.G., Ferrario M.G., Poussin-Courmontagne P., et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science 2013, 339(6120):694-698.
85. Vande Pol S.B., Klingelhutz A.J. Papillomavirus E6 oncoproteins. Virology 2013, 445(1-2):115-137.
86. Pim D., Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS 2010, 118(6-7):471-493.
87. Huibregtse J.M., Scheffner M., Howley P.M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991, 10:4129-4136.
88. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
89. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75(3):495-505.
90. Patel D., Huang S.M., Baglia L.A., McCance D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999, 18(18):5061-5072.
91. Klingelhutz A.J., Foster S.A., McDougall J.K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996, 380(6569):79-82.
92. Shay J.W., Wright W.E. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis 2005, 26(5):867-874.
93. Gewin L., Myers H., Kiyono T., Galloway D.A. Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 2004, 18(18):2269-2282.
94. Liu X., Yuan H., Fu B., Disbrow G.L., Apolinario T., Tomaic V., et al. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 2005, 280(11):10807-10816.
95. James M.A., Lee J.H., Klingelhutz A.J. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol 2006, 80(11):5301-5307.
96. Xu M., Katzenellenbogen R.A., Grandori C., Galloway D.A. NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J Virol 2010, 84(21):11461-11469.
97. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc Natl Acad Sci U S A 2003, 100(14):8211-8216.
98. Sekaric P., Cherry J.J., Androphy E.J. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. J Virol 2008, 82(1):71-76.
99. Bedard K.M., Underbrink M.P., Howie H.L., Galloway D.A. The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. J Virol 2008, 82(8):3894-3902.
100. Cornet I., Bouvard V., Campo M.S., Thomas M., Banks L., Gissmann L., et al. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types. J Virol 2012, 86(4):2366-2370.
101. Jackson S., Harwood C., Thomas M., Banks L., Storey A. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000, 14(23):3065-3073.
102. Thomas M., Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17(23):2943-2954.
103. Underbrink M.P., Howie H.L., Bedard K.M., Koop J.I., Galloway D.A. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 2008, 82(21):10408-10417.
104. Nguyen M.L., Nguyen M.M., Lee D., Griep A.E., Lambert P.F. The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol 2003, 77(12):6957-6964.
105. Watson R.A., Thomas M., Banks L., Roberts S. Activity of the human papillomavirus E6 PDZ-binding motif correlates with an enhanced morphological transformation of immortalized human keratinocytes. J Cell Sci 2003, 116(Pt 24):4925-4934.
106. Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001, 20(54):7874-7887.
107. Huh K., Zhou X., Hayakawa H., Cho J.Y., Libermann T.A., Jin J., et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 2007, 81(18):9737-9747.
108. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005, 24(17):2796-2809.
109. Dimova D.K., Dyson N.J. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005, 24(17):2810-2826.
110. Zhang B., Chen W., Roman A. The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. Proc Natl Acad Sci U S A 2006, 103(2):437-442.
111. Attwooll C., Oddi S., Cartwright P., Prosperini E., Agger K., Steensgaard P., et al. A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem 2005, 280(2):1199-1208.
112. Trimarchi J.M., Fairchild B., Verona R., Moberg K., Andon N., Lees J.A. E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc Natl Acad Sci U S A 1998, 95(6):2850-2855.
113. McLaughlin-Drubin M.E., Huh K.W., Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol 2008, 82(17):8695-8705.
114. Funk J.O., Waga S., Harry J.B., Espling E., Stillman B., Galloway D.A. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997, 11(16):2090-2100.
115. Jones D.L., Alani R.M., Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev 1997, 11(16):2101-2111.
116. Zerfaß-Thome K., Zwerschke W., Mannhardt B., Tindle R., Botz J., Jansen-Dürr P. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 1996, 13:2323-2330.
117. Tommasino M., Adamczewski J.P., Carlotti F., Barth C.F., Manetti R., Contorni M., et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993, 8(1):195-202.
118. He W., Staples D., Smith C., Fisher C. Direct activation of cyclin-dependent kinase 2 by human papillomavirus E7. J Virol 2003, 77(19):10566-10574.
119. Accardi R., Scalise M., Gheit T., Hussain I.S., Yue J., Carreira C., et al. IκB kinase β promotes cell survival by antagonizing p53 functions through δNp73α phosphorylation and stabilization. Mol Cell Biol 2011, 31(11):2210-2226.
120. Saidj D., Cros M.P., Hernandez-Vargas H., Guarino F., Sylla B., Tommasino M., et al. The E7 oncoprotein from beta human papillomavirus type 38 induces the formation of an inhibitory complex for a subset of p53-regulated promoters. J Virol 2013, 87(22):12139-12150.
121. Accardi R., Fathallah I., Gruffat H., Mariggio G., Le Calvez-Kelm F., Voegele C., et al. Epstein-Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein DeltaNp73alpha. PLoS Pathog 2013, 9(3):e1003186.
122. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384(2):335-344.
123. zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res 1976, 36(2 pt 2):794.